title: [Is Plasmodium vivax still a paradigm for uncomplicated malaria?].
abstract: P. vivax is supposed to be involved in benign tertian fever, responsible for a non-complicated disease that could be easily treated by standard antimalarial drug regimen. This could be considered as a long-standing paradigm of a non-virulent malaria parasite. When a patient exhibits severe malaria with the vivax parasite, the issue is often to find falciparum. However, with the implementation of molecular diagnosis, it has becoming more evident that vivax parasites could be involved in severe disease with probably a different pathogenesis. Mixed infections are frequent in various parts of Southeast Asian endemic areas and it was speculated that drugs used to treat falciparum could be involved in the development of vivax drug resistance. How should primaquine be used today for the treatment and prophylaxis of vivax malaria? Considering the re-emergence of vivax malaria in several areas, improving the treatment for this disease is certainly an important issue to avoid late episodes and transmission potential.
authors.affiliation: EA 37-32, virulence et résistance de plasmodium, faculté de médecine de Lyon, université Claude-Bernard, 69373 Lyon, France. picot@sante.univ-lyon1.fr
authors.forename: S
authors.initials: S
authors.lastname: Picot
mesh_terms: D000818:Animals; D006801:Humans; D007113:Immunity, Innate; D016780:Malaria, Vivax / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology* / Q000635:transmission; D010966:Plasmodium vivax / Q000502:physiology; D014195:Travel